National Advisory Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary series

The National Advisory Committee on Immunization (NACI) is an External Advisory Body that provides the Public Health Agency of Canada (PHAC) with independent, ongoing and timely medical, scientific, and public health advice in response to questions from PHAC relating to immunization.

This statement contains NACI's independent advice and recommendations, which are based upon the best current available scientific knowledge. This document is being disseminated for information purposes. People administering the vaccine should also be aware of the contents of the relevant product monograph. Recommendations for use and other information set out herein may differ from that set out in the product monographs of the Canadian manufacturers of the vaccines. Manufacturer(s) have sought approval of the vaccines and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. NACI members and liaison members conduct themselves within the context of PHAC's Policy on Conflict of Interest, including yearly declaration of potential conflict of interest.

Données et ressources

Info additionnelle

Champ Valeur
Dernière modification avril 17, 2026, 21:23 (TU)
Créé le avril 17, 2026, 21:23 (TU)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2021-09-10 00:00:00
open_canada_keywords {"fr": ["Réponse", "rapide", "Comité", "consultatif", "national", "immunisation", "CCNI", "Dose", "supplémentaire", "vaccin", "contre", "la COVID-19", "chez", "sujets", "immunodéprimés", "après", "série", "primaire", "1 ou 2 doses", "COVID", "pandémie", "COVID-19", "Coronavirus", "Vaccins", "immunisation", "Comité", "consultatif", "national", "immunisation", "Déclarations", "publications", "Recommandations", "utilisation", "vaccins", "Méthodologie", "Résumé", "données", "probantes", "Fardeau", "la maladie", "Canada", "Sommaire", "probantes", "série", "deux doses", "personnes", "immunodéprimées", "dose", "supplémentaire", "après", "autres", "renseignements", "facteurs", "prendre", "considération", "Recommandations", "Priorités", "recherche", "Références", "Abréviations", "Remerciements", "Abréviation", "ARNm", "Acide", "ribonucléique", "messager", "ASPC", "Agence", "santé", "publique", "Canada", "CCNI", "IC", "Intervalle de confiance", "SRAS-CoV-2", "Coronavirus", "syndrome", "respiratoire", "aigu sévère 2"], "en": ["pandemic", "COVID-19", "Coronavirus", "COVID", "Vaccines", "immunization", "National", "Advisory", "Committee", "Immunization", "NACI", "Statements", "publications", "Recommendations", "on the use", "of COVID-19", "vaccines", "rapid", "response", "Additional", "dose", "vaccine", "immunocompromised", "individuals", "1 dose", "2 dose", "primary", "series", "Methods", "CI", "Confidence interval", "coronavirus disease", "2019", "mRNA", "messenger", "ribonucleic acid", "PHAC", "Public", "Health", "Agency", "Canada", "SARS-CoV-2", "Severe", "Acute", "Respiratory", "Syndrome", "Coronavirus 2", "Summary", "evidence", "Burden", "illness", "2-dose", "series", "additional", "dose", "Additional", "information", "considerations", "Recommendations", "Research", "priorities", "References", "Abbreviations"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Réponse rapide du Comité consultatif national de l'immunisation (CCNI) : Dose supplémentaire de vaccin contre la COVID-19 chez les sujets immunodéprimés après une série primaire de 1 ou 2 doses
update_frequency unknown